Kexing Biopharm Co Ltd
SSE:688136
Kexing Biopharm Co Ltd
SSE:688136
Price:
30.84
CNY
-1.56%
Market Closed
Market Cap:
¥6.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Kexing Biopharm Co Ltd
SSE:688136
|
CN |
|
M
|
Maxicity Holdings Ltd
HKEX:2295
|
HK |
|
L
|
Luxe Holdings Ltd
JSE:LUX
|
ZA |
|
A
|
Agristar Inc
OTC:AGRS
|
US |
Income Statement
Earnings Waterfall
Kexing Biopharm Co Ltd
Kexing Biopharm Co Ltd
Income Statement
Kexing Biopharm Co Ltd
Kexing Biopharm Co Ltd
Currency: CNY
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
16
|
17
|
16
|
11
|
10
|
11
|
9
|
13
|
18
|
29
|
33
|
38
|
40
|
41
|
39
|
41
|
42
|
45
|
44
|
0
|
|
| Revenue |
1 220
N/A
|
1 220
+0%
|
1 152
-6%
|
1 250
+8%
|
1 225
-2%
|
1 285
+5%
|
1 278
-1%
|
1 319
+3%
|
1 333
+1%
|
1 316
-1%
|
1 369
+4%
|
1 335
-2%
|
1 341
+0%
|
1 259
-6%
|
1 297
+3%
|
1 370
+6%
|
1 328
-3%
|
1 407
+6%
|
1 400
-1%
|
1 347
-4%
|
|
| Gross Profit | |||||||||||||||||||||
| Cost of Revenue |
(227)
|
(245)
|
(244)
|
(272)
|
(266)
|
(265)
|
(285)
|
(301)
|
(327)
|
(325)
|
(361)
|
(370)
|
(378)
|
(370)
|
(391)
|
(415)
|
(417)
|
(444)
|
(468)
|
(490)
|
|
| Gross Profit |
992
N/A
|
975
-2%
|
908
-7%
|
977
+8%
|
959
-2%
|
1 020
+6%
|
993
-3%
|
1 018
+3%
|
1 005
-1%
|
991
-1%
|
1 008
+2%
|
965
-4%
|
963
0%
|
889
-8%
|
906
+2%
|
955
+5%
|
911
-5%
|
963
+6%
|
932
-3%
|
857
-8%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(785)
|
(801)
|
(786)
|
(857)
|
(858)
|
(975)
|
(965)
|
(1 034)
|
(1 113)
|
(1 115)
|
(1 170)
|
(1 166)
|
(1 078)
|
(1 122)
|
(1 107)
|
(1 027)
|
(974)
|
(839)
|
(794)
|
(750)
|
|
| Selling, General & Administrative |
(724)
|
(727)
|
(718)
|
(781)
|
(764)
|
(838)
|
(830)
|
(878)
|
(946)
|
(896)
|
(965)
|
(937)
|
(847)
|
(752)
|
(779)
|
(731)
|
(691)
|
(667)
|
(648)
|
(602)
|
|
| Research & Development |
(53)
|
(56)
|
(63)
|
(71)
|
(92)
|
(111)
|
(138)
|
(160)
|
(171)
|
(172)
|
(212)
|
(238)
|
(238)
|
(316)
|
(331)
|
(301)
|
(290)
|
(141)
|
(170)
|
(169)
|
|
| Depreciation & Amortization |
(8)
|
(14)
|
0
|
0
|
0
|
(29)
|
0
|
0
|
0
|
(50)
|
0
|
0
|
0
|
(62)
|
0
|
0
|
0
|
(56)
|
0
|
0
|
|
| Other Operating Expenses |
0
|
(5)
|
(5)
|
(5)
|
(1)
|
2
|
3
|
3
|
4
|
3
|
7
|
7
|
6
|
8
|
3
|
4
|
7
|
25
|
24
|
21
|
|
| Operating Income |
208
N/A
|
174
-16%
|
122
-30%
|
120
-2%
|
101
-16%
|
45
-55%
|
28
-39%
|
(16)
N/A
|
(108)
-572%
|
(124)
-15%
|
(162)
-31%
|
(201)
-24%
|
(115)
+43%
|
(233)
-102%
|
(201)
+14%
|
(73)
+64%
|
(62)
+14%
|
123
N/A
|
138
+12%
|
107
-23%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(19)
|
(14)
|
(17)
|
(10)
|
(0)
|
53
|
48
|
41
|
41
|
(16)
|
(24)
|
(1)
|
(10)
|
(24)
|
(23)
|
(63)
|
(66)
|
(60)
|
(57)
|
(5)
|
|
| Non-Reccuring Items |
(1)
|
(1)
|
0
|
2
|
2
|
(0)
|
(1)
|
(2)
|
(1)
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
(2)
|
(1)
|
(1)
|
(0)
|
(1)
|
(1)
|
(3)
|
(2)
|
(4)
|
(9)
|
(7)
|
(6)
|
(9)
|
(3)
|
|
| Pre-Tax Income |
187
N/A
|
159
-15%
|
105
-34%
|
111
+6%
|
102
-9%
|
96
-6%
|
73
-23%
|
22
-70%
|
(69)
N/A
|
(139)
-101%
|
(187)
-34%
|
(204)
-9%
|
(128)
+37%
|
(260)
-103%
|
(227)
+13%
|
(145)
+36%
|
(135)
+7%
|
57
N/A
|
73
+28%
|
99
+36%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
(29)
|
(20)
|
(5)
|
(6)
|
(5)
|
1
|
6
|
17
|
32
|
46
|
55
|
58
|
35
|
65
|
53
|
9
|
12
|
(30)
|
(32)
|
(3)
|
|
| Income from Continuing Operations |
158
|
139
|
100
|
105
|
97
|
96
|
79
|
38
|
(37)
|
(93)
|
(132)
|
(145)
|
(93)
|
(195)
|
(174)
|
(136)
|
(124)
|
27
|
40
|
97
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
4
|
4
|
5
|
5
|
5
|
5
|
5
|
4
|
4
|
3
|
|
| Net Income (Common) |
158
N/A
|
139
-12%
|
100
-28%
|
105
+5%
|
97
-8%
|
96
-1%
|
79
-18%
|
39
-51%
|
(36)
N/A
|
(90)
-154%
|
(128)
-42%
|
(141)
-10%
|
(88)
+38%
|
(190)
-117%
|
(169)
+11%
|
(131)
+23%
|
(119)
+9%
|
31
N/A
|
45
+42%
|
100
+124%
|
|
| EPS (Diluted) |
0.8
N/A
|
0.93
+16%
|
0.51
-45%
|
0.53
+4%
|
0.48
-9%
|
0.49
+2%
|
0.4
-18%
|
0.2
-50%
|
-0.17
N/A
|
-0.45
-165%
|
-0.64
-42%
|
-0.7
-9%
|
-0.43
+39%
|
-0.96
-123%
|
-0.81
+16%
|
-0.67
+17%
|
-0.68
-1%
|
0.16
N/A
|
0.23
+44%
|
0.51
+122%
|
|
Switch to:
Switch to:
See Also
Discover More
